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OBJECTIVE: Clinical trials are often the best source of efﬁ-
cacy data for economic evaluations of medical interventions.
However, their reliability can be compromised when patients
cross-over from control to experimental treatment. In two trials
evaluating lenalidomide (Len) plus high-dose dexamethasone
(Dex) vs Dex alone (MM-009/010) in patients with multiple
myeloma (MM), 47% of patients in the Dex alone group were
switched to Len +/- Dex at disease progression or following
study unblinding. Given the signiﬁcant efﬁcacy beneﬁts of
Len + Dex over Dex alone, the trial data will overestimate the
survival with Dex alone biasing the results. METHODS: Exter-
nal data from the UK Medical Research Council (MRC) MM-IV,
V, VI, and VIII trials enrolled between 1980 and 1997 were used
to derive an equation reﬂecting survival without lenalidomide,
including prognostic variables to enable adjustment for differ-
ences between the MRC and MM-009/010 trials. Applying the
MRC equation to the MM-009/010 Dex patient characteristics
yielded expected median survival time without cross-over to
Len +/- Dex. This was used to calibrate the economic model for
the Dex alone group by correcting the scale parameter of the
underlying Weibull survival equation, estimated from MM-009/
010, assuming the shape parameter remained the same.
RESULTS: Of 873 MRC patients, 826 died. Exponential survival
ﬁt the data, with age, MM performance status, M-protein level,
B2M level and time to progression as predictors. Applied to
MM-009/010 Dex patient characteristics, this yielded a median
survival of 14.9 months (95%CI: 12.3–18.0) (compared to 31
months (95%CI: 25.7–35.1) observed with cross-over in
MM-009/010). Incorporating the corrected survival function
into the economic model resulted in an estimated incremental
2.8 life-years and 1.9 QALYs gained per patient treated with
Len + Dex vs Dex alone. CONCLUSION: Using external data to
adjust estimation equations can mitigate the impact on economic
evaluations resulting from cross-over or other distorting factors
in clinical trials.
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OBJECTIVE: To describe patient characteristics, doses taken,
reason for exposure, time of exposure, treatment and severity of
poisoning in adults with acetaminophen-related exposures
reported to a regional poison control center (RPCC).
METHODS: A retrospective review was conducted of all
acetaminophen exposures that occurred between October 31,
2000 and October 31, 2003 in adults over 18 years of age who
were managed by a RPCC. Data collected included patient demo-
graphics, amount ingested, severity of exposure, time since expo-
sure, treatment, reason for exposures, exposure site, and caller
site. RESULTS: There were 175 exposures to acetaminophen;
72% were females and 28% were males in the study population.
There was no signiﬁcant difference between the mean age of
females (31.2  14.0) and males (30.9 12.3) in years. The
mean dose of acetaminophen taken was 18.7  20.4 grams and
no signiﬁcant difference in the amount ingested between males
and females. The majority of the callers seeking information on
acetaminophen ingestion were health care professionals (68%).
The mean time between the exposure and the call made to the
RPCC was 11.27  18.54 hours. Fifty percent of the patients
received acetylcysteine therapy, 27.4% received decontamination
(e.g., activated charcoal), and 22.3% received other interventions
for the treatment of acetaminophen poisoning. Females (72.4%)
were more likely (p < 0.001) to take intentional overdoses than
males (27.6%). The most common acetaminophen exposure site
was patient’s own residence (96%). The majority of the expo-
sures were acute (86.9%) rather than chronic poisoning. CON-
CLUSION: The main reason for acetaminophen exposure was
intentional and females were more likely to ingest intentionally
than males. Contacting the RPCC for advice generally occurred
beyond the time for optimal acetylcysteine effectiveness. The
majority of the exposures were due to acute poisoning.
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OBJECTIVE: To determine the economic impact of increased
prevalence of cardiometabolic risk (CMR) factors including high
blood pressure (BP), loss of glycemic control (DB), high triglyc-
erides (TG) and decreased high density lipoproteins (HDL) in
commercially insured overweight patients [Body Mass Index
(BMI) > 27 kg/m2] compared to normal weight (18  BMI <
27 kg/m2). METHODS: Patients 18–65 years old were identiﬁed
from an electronic medical record database (EMR) with CMR
factors designated by prescription orders or ICD-9 codes and
grouped into normal or overweight categories. Similar patients
with CMR factors were identiﬁed in Medstat MarketScan®
administrative claims database. Using a multivariate two-part
regression model, costs from this database were estimated for
CMR factors. Probabilities of being normal or overweight from
the EMR database were applied to the estimated costs to obtain
per patient total annual medical costs for CMR factors stratiﬁed
by normal and overweight groups. RESULTS: A total of 75,578
patients with CMR factors were identiﬁed in the EMR. Normal
[18,213 (24%)] versus overweight patients [57,365 (76%)] were
distributed as follows: BP, 29% vs. 71%; DB, 19% vs. 81%; TG,
25% vs. 75%; HDL, 37% vs. 63%; any 2 CMR factors, 13% vs.
87%; any 3 CMR factors, 9% vs. 91%; and all 4 CMR factors,
6% vs. 94%. Estimated costs from the claims database were:
high BP, $1630; DB, $1748; high TG’s, $638; low HDL, $1474;
and $2606, $2801, $3191 for 2, 3, and 4 CMR factors, respec-
tively. Applying the probability of normal or overweight and the
estimated costs to the distribution of CMR factors resulted in an
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